CLYM

Analyst Note: CLYM (Climb Bio, Inc.)

Date: 2026-06-13 Price: $11.45

1. Structural Readiness

• Conservative Entry: Not yet triggered (awaiting confirmed breakout above resistance).
• Aggressive/Pre-Breakout Entry: $11.45 (Current Price).
• Breakout Level: Not yet established; requires a close above the immediate consolidation high.
• Current Price: $11.45.
• Extension: Not applicable (price is within the consolidation range, not extended above the breakout level).
• ATR Context: Current ATR is 8.4% (Extreme). This indicates high volatility and significant risk of whipsaw during the forming phase. Historically, extreme ATR levels correlate with higher failure rates for setups that do not immediately resolve into a trend.

2. Thesis Layer

• Primary Secular Thesis: Biotech & GLP-1 → Immunology & Inflammation.
• Directness: Tier Direct / High Confidence.
• Climb Bio is a pure-play clinical-stage biotechnology company focused exclusively on immune-mediated diseases. The company's pipeline (Budoprutug and CLYM116) targets specific unmet needs within the immunology sector (pMN, ITP, SLE, IgAN).
• The company is a direct beneficiary of the secular shift toward targeted monoclonal antibodies for autoimmune conditions, positioning itself as a potential best-in-class developer in a high-cost, high-need market segment.
• Additional Tailwinds: The evidence highlights a massive addressable market (2.0 million people in the U.S. with immune-mediated diseases) and a collective healthcare cost of over $100 billion annually, providing a strong secular backdrop for capital allocation in this space.

3. Business Overview

• Company Role: Climb Bio is a clinical-stage biotechnology company developing potential best-in-class therapeutics for immune-mediated diseases.
• Business Model: The company operates on a standard biotech model: developing proprietary monoclonal antibodies through clinical trials, securing regulatory clearances (IND/CTA), and aiming for commercialization or licensing.
• Key Assets & Status (as of 2026-06-13):
• Budoprutug (Anti-CD19):
• *Indications:* Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE).
• *Status:*
• pMN: Phase 2 dose-ranging trial (PrisMN) initiated in November 2025; actively enrolling. FDA clearance received March 2025.
• ITP: Phase 1b/2a trial cleared by FDA in March 2025.
• SC Formulation: Phase 1 trial in healthy volunteers in Australia completed; management expects data release in the first half of 2026 (Evidence E10).
• SLE: Phase 1b trial in China initiated December 2025; parallel global Phase 1b trial ongoing.
• CLYM116 (Anti-APRIL):
• *Indication:* Immunoglobulin A Nephropathy (IgAN).
• *Status:* Phase 1 trial in healthy volunteers in Australia initiated October 2025 (Evidence E13).
• Commercial Rights: Worldwide rights for Budoprutug (excluding oncology) and CLYM116 (excluding Greater China).
• Financial Context:
• Management estimates that cash, cash equivalents, and marketable securities (including proceeds from a private placement in April 2026) are sufficient to fund operating expenses and capital expenditures for a defined period (Evidence E2).
• The company anticipates the timing of IND submissions and clearances for both assets (Evidence E1).

4. Archetype and Conviction

• Archetype: Growth Leader.
• *Fit:* The company is in the high-growth phase of clinical development, moving from early-stage trials to mid-stage (Phase 2) and generating data readouts. The focus on "best-in-class" therapeutics and the expansion into multiple indications (pMN, ITP, SLE) aligns with the Growth Leader profile.
• Valuation & Conviction Stack:
• Thesis Strength: High. The secular tailwinds in immunology are robust, and the company has a clear, focused pipeline.
• Evidence Quality: Strong. Multiple SEC filings (March and May 2026) confirm active enrollment, regulatory clearances, and specific timelines for data readouts.
• Structural Quality: Moderate to Weak. While the business fundamentals are sound, the Current ATR of 8.4% (Extreme) is a significant structural headwind. In the StoryStocks canon, extreme ATR (>8%) is associated with the highest historical severe-loser rates. This suggests the stock is prone to violent moves that can invalidate technical setups before the fundamental thesis plays out.
• Setup Readiness: Partial. The coil is "Forming," meaning the structure is present but the breakout has not fired. The high volatility makes a clean breakout difficult to distinguish from noise.
• Rerating Potential: High, contingent on the successful release of the SC formulation data (H1 2026) and the progression of the Phase 2 PrisMN trial.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• Negative data readout from the Phase 2 PrisMN trial or the SC formulation Phase 1 data (fundamental invalidation).
• A significant delay in the anticipated IND submissions or clearances mentioned in the May 2026 filing.
• What Would Strengthen:
• A confirmed breakout above the consolidation resistance with volume.
• Positive top-line data from the Australian SC formulation trial (expected H1 2026).
• Confirmation of the cash runway extension beyond current estimates.
• Gaps in Evidence:
• Specific Cash Runway Duration: While the May 2026 filing mentions the cash is "sufficient," the exact number of months of runway is not explicitly quantified in the provided evidence snippets.
• Phase 2 Data Readout Date: The filing confirms the trial is "actively enrolling" (March 2026), but the specific date for the top-line data readout for the Phase 2 PrisMN trial is not provided in the evidence block.
• Revenue Projections: As a clinical-stage company, specific revenue figures are not yet available; the evidence focuses on expenses and capital requirements.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Active Phase 2 enrollment in PrisMN (pMN) with FDA clearance; Positive secular tailwinds in immunology with 2.0M US patient addressable market; Recent private placement in April 2026 provides near-term liquidity. Key risks: Extreme ATR (8.4%) indicates high volatility and potential for whipsaw; Clinical trial failure risk in pMN or ITP indications; Uncertainty regarding exact cash runway duration beyond current estimates. Sizing hint: Position size must be reduced significantly to account for the extreme ATR and the "forming" (unconfirmed) nature of the technical setup. Expected path: Management expects data release from the SC formulation trial in H1 2026; if data is positive, the stock may attempt a breakout from the current consolidation range. Expected horizon: 6 to 12 months for the next major catalyst (Phase 2 data or SC data readout).